Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 452-459

  Yousef, Jumana M ^a   Chen, Gong ^a   Hill, Prue A ^b   Nation, Roger L ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Polymyxin E; Rat kidney tubular cells; Vitamin C

Indexed keywords

ASCORBIC ACID; COLISTIN; N ACETYL BETA GLUCOSAMINIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG CLEARANCE; DRUG EFFECT; HISTOLOGY; IN VITRO STUDY; KIDNEY CELL; KIDNEY PROXIMAL TUBULE; MALE; NEPHROTOXICITY; NONHUMAN; RAT; RENAL PROTECTION; URINARY EXCRETION;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; ASCORBIC ACID; CELLS, CULTURED; COLISTIN; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; RATS; RATS, SPRAGUE-DAWLEY; VITAMINS;

EID: 84862965997     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr483     Document Type: Article

References (45)

1. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960-7.
2. Falagas ME, Kasiakou SK, Falagas ME et al. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
3. Landman D, Georgescu C, Martin DA et al. Polymyxins revisited. Clin Microbiol Rev 2008; 21: 449-65.
4. Li J, Nation RL, Milne RWet al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25.
5. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
6. Bergen PJ, Li J, Rayner CR et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-8.
7. Holmes KK. Toxicity of colistin and polymixin B. N Engl J Med 1964; 271: 633-4.
8. Horton J, Pankey GA. Polymyxin B, colistin, and sodium colistimethate. Med Clin North Am 1982; 66: 135-42.
9. Koch-Weser J, Sidel VW, Federman EB et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-68.
10. Nord NM, Hoeprich PD. Polymyxin B and colistin: a critical comparison. N Engl J Med 1964; 270: 1030-5.
11. Falagas ME, Fragoulis KN, Kasiakou SK et al. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005; 26: 504-7.
12. Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-8.
13. Kallel H, Hergafi L, Bahloul M et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33: 1162-7.
14. Ko HJ, Jeon MH, Choo EJ et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011; 117: c284-8.
15. Koomanachai P, Tiengrim S, Kiratisin P et al. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007; 11: 402-6.
16. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
17. Antoniadou A, Kontopidou F, Poulakou G et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007; 59: 786-90.
18. Beno P, Krcmery V, Demitrovicova A. Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clin Microbiol Infect 2006; 12: 497-8.
19. Ozyilmaz E, Ebinc FA, Derici U et al. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med 2010; 37: 141-6.
20. Yousef JM, Chen G, Hill PA et al. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011; 55: 4044-9.
21. Lopez-Novoa JM, Quiros Y, Vicente L et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011; 79: 33-45.
22. Padh H. Cellular functions of ascorbic acid. Biochem Cell Biol 1990; 68: 1166-73.
23. Tolbert BM. Metabolism and function of ascorbic acid and its metabolites. Int J Vitam Nutr Res Suppl 1985; 27: 121-38.
24. Niki E. Action of ascorbic acid as a scavenger of active and stable oxygen radicals. Am J Clin Nutr 1991; 54: 1119S-24S.
25. Antunes LM, Darin JD, Bianchi MD. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res 2000; 41: 405-11.
26. Ben Ismail TH, Ali BH, Bashir AA. Influence of iron, deferoxamine and ascorbic acid on gentamicin-induced nephrotoxicity in rats. Gen Pharmacol 1994; 25: 1249-52.
27. Kadkhodaee M, Khastar H, Arab HA et al. Antioxidant vitamins preserve superoxide dismutase activities in gentamicin-induced nephrotoxicity. Transplant Proc 2007; 39: 864-5.
28. Kadkhodaee M, Khastar H, Faghihi M et al. Effects of co-supplementation of vitamins E and C on gentamicin-induced nephrotoxicity in rat. Exp Physiol 2005; 90: 571-6.
29. Ocak S, Gorur S, Hakverdi S et al. Protective effects of caffeic acid phenethyl ester, vitamin C, vitamin E and N-acetylcysteine on vancomycin-induced nephrotoxicity in rats. Basic Clin Pharmacol Toxicol 2007; 100: 328-33.
30. Bendich A, Cohen M. Ascorbic acid safety: analysis of factors affecting iron absorption. Toxicol Lett 1990; 51: 189-201.
31. Li J, Milne RW, Nation RL et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003; 47: 1364-70.
32. Horak E, Hopfer SM, Sunderman FW Jr. Spectrophotometric assay for urinary N-acetyl-b-D-glucosaminidase activity. Clin Chem 1981; 27: 1180-5.
33. Li J, Milne RW, Nation RL et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chrom B Biomed Sci Appl 2001; 761: 167-75.
34. Nation RL, Li J. Optimizing use of colistin and polymyxin B in the critically ill. Semin Respir Crit Care Med 2007; 28: 604-14.
35. Ko KS, Suh JY, Kwon KT et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007; 60: 1163-7.
36. Li J, Turnidge J, Milne R et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 781-5.
37. Nation RL, Li J, Nation RL et al. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22: 535-43.
38. Schwartz BS, Warren MR, Barkley FA et al. Microbiological and pharmacological studies of colistin sulfate and sodium colistinmethanesulfonate. Antibiot Annu 1959; 7: 41-60.
39. Ajith TA, Usha S, Nivitha V. Ascorbic acid and a-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta 2007; 375: 82-6.
40. Food and Nutrition Board of Institute of Medicine. DRI Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids. Washington, DC: National Academy Press, 2000.
41. Lockwood TD, Bosmann HB. The use of urinary N-acetyl-b-glucosaminidase in human renal toxicology. I. Partial biochemical characterization and excretion in humans and release from the isolated perfused rat kidney. Toxicol Appl Pharmacol 1979; 49: 323-36.
42. Wallace SJ, Li J, Nation RL et al. Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother 2008; 52: 1159-61.
43. Li J, Milne RW, Nation RL et al. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47: 1766-70.
44. Ma Z, Wang J, Nation RL et al. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother 2009; 53: 2857-64.
45. Rumsey SC, Levine M. Absorption, transport, and disposition of ascorbic acid in humans. J Nutr Biochem 1998; 9: 116-30.